REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Research/Paper
Back to Research Library
PubMedClinical Trial

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.

Del Prato Stefano, Kahn Steven E, Pavo Imre, Weerakkody Govinda J, Yang Zhengyu, Doupis John, Aizenberg Diego, Wynne Alan G, Riesmeyer Jeffrey S, Heine Robert J
Lancet (London, England)2021DOI: 10.1016/S0140-6736(21)02188-7

Citations

0

Subjects

Non-Human

Study Context

This clinical trial followed a structured protocol to evaluate outcomes. The controlled methodology adds credibility to the reported results.

Why This Matters

This research contributes to the growing body of evidence on tirzepatide. Understanding the mechanisms and clinical applications of these peptides is an active area of investigation.

Citation

Del Prato Stefano, Kahn Steven E, Pavo Imre et al.. (2021). Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/S0140-6736(21)02188-7

View full text on PubMed

This content is derived from peer-reviewed research for educational purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide-based therapy.